Miltuximab® for Therapeutic & Imaging Applications.

Our patented antibodies target Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.
We are examining multiple mechanisms of action including:

  • Radio immunotherapy
  • Bispecific antibodies
  • Immune cell engagement and activation

We have now completed a first in-human trial using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry).

The trial dosed 12 patients and no drug-related adverse events were observed.

Glytuzumab® refers to the humanized version of Miltuximab® and also targets human GPC-1. The Glytuzumab® program is currently undergoing Lead Optimisation and Lead Selection stages. Several humanized leads have been generated with similar binding affinities as that of the parent molecule Miltuximab®. The final Glytuzumab® lead selected will be taken forward from cell line development through to large scale GMP production for future clinical trials.




First-In-Human Clinical trial of Miltuximab® conjugated to 67Gallium for imaging met primary endpoint of safety in all patients

Preclinical work now completed for upcoming Phase I Clinical trial in GPC-1 expressing solid tumours. This will use Miltuximab® labelled with either 89Zirconium for imaging or 177Lutetium for therapy

Antibody composition of matter patents granted EU and US



Completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers



The second stage of pioneering MILGa clinical trial of Miltuximab®



Commenced First-In-Human trial of Miltuximab® 

2015 Eureka Prize

Excellence in Interdisciplinary Scientific Research

Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.

Find Out More Information

  • About our groundbreaking first-in-human trial of our novel cancer target >More
  • About how your company and Glytherix could partner to deliver better cancer therapeutics >More 

5 + 9 =

Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 

International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here


Finding Us
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Headquarters of Glytherix

Privacy Policy